Please login to the form below

Not currently logged in
Email:
Password:

Ultragenyx

This page shows the latest Ultragenyx news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs. Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. ... The FDA gave the go-ahead to a pair of rare disease therapies this week, both marking the first-ever

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    The research collaboration between Arcturus Therapeutics and Ultragenyx Pharmaceutical covers the discovery and development of mRNA therapeutics to certain rare disease targets using the Arcturus UNA Oligomer chemistry and LUNAR nanoparticle

  • Pharma deals during January 2013 Pharma deals during January 2013

    Deal Type. Comments. Baylor Research Institute. Ultragenyx. Collaboration. Triheptanoin UX 007 in rare and ultra-rare diseases. ... For example, Ultragenyx has in-licensed triheptanoin for long-chain fatty acid oxidation disorders from the Baylor

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Genentech’s Sunil Agarwal joins rare disease firm Genentech’s Sunil Agarwal joins rare disease firm

    Genentech’ s Sunil Agarwal joins rare disease firm. He will serve as chief medical officer at Ultragenyx. ... Dr Sunil Agarwal has left his senior role at Genentech to join rare disease specialist Ultragenyx Pharmaceutical as its chief medical officer.

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics